Sample Collection PK AssessmentsSee Table 9.5-1 , Table 9.5-2 , Table 9.5- 3, and Table 9.5-4See Section 9.5 . Revised Protocol No.: 04 Date: 31-May-2019 31 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-3: Follow-up Procedural Outline (CA021002) ProcedureSafety Follow-upaSurvival/Response Long-term Follow-up NotesFU 1 30 days (±±7 days) FU 2 60 days (±7 days)FU 3 100 days (±7 days)Begins After Completion of Safety Follow-up Q12W (Q12W ±2 weeks) Until 2 Years After Last Dose of Study Treatment Immunogenicity (eg, ADA) Assessments Efficacy Assessments Body Imaging X XbSee Section 9.1 . Participants should undergo tumor assessment via CT/MRI scans at least Q12W during the survival follow-up period until beginning a new anti-cancer therapy.